Key Dates

Related Announcements

• December 13, 2023 - -Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R01 Clinical Trial Optional). See NOFO PAR-23-319

Issued by

Fogarty International Center (FIC)

Purpose

This notice adds the priority/interests language for the National Eye Institute (NEI) to the PAR-23-319 Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R01 Clinical Trial Optional).

Currently reads: 

Section I. Notice of Funding Opportunity Description

NIH IC-Specific Priorities

Changed to read (adding in the text):

Section I. Notice of Funding Opportunity Description

NIH IC-Specific Priorities

National Eye Institute (NEI)

NEI’s mission is to eliminate vision loss and improve quality of life through vision research.  NEI encourages applications pursuing innovative approaches to adapt, integrate and scale-up implementation of evidence-based interventions addressing NCD risk factors for vision impairment and blindness, in the context of cities in LMICs and among AI/AN communities in US cities.  Examples of NCD risk factors include environmental exposures, occupational hazards, high intraocular pressure, diabetes or impaired glucose tolerance.  Specific areas of interest include but are not limited to:

• Research that investigates strategies to expand access to and assess the clinical utility of ophthalmic imaging technologies in urban hospitals and clinics.
• Research that culturally tailors and evaluates the effectiveness (or lack thereof) of vision screening programs and early eye disease detection/diagnostic interventions in urban settings.
• Research that builds on evidence-based findings to reduce or stop (i.e., “de-implement”) the use of clinical or community practices that are ineffective, unproven, biased or harmful in the management of eye and vision conditions.

NEI will not support clinical trials that are greater than minimal risk on this funding opportunity.  Minimal risk is defined as the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.  For additional information on NEI Clinical Trial policies, see NOT-EY-23-001.

Applicants are strongly advised to reach out to the NEI Scientific Contact before submitting applications for guidance about NEI’s interests, the NEI Strategic Plan (Vision for the Future 2021-2025 https://www.nei.nih.gov/about/strategic-planning), and more information regarding clinical trial designations.

Inquiries

Please direct all inquiries to:

Brad Newsome, Ph.D.
Fogarty International Center (FIC)
Telephone: 301-480-8389
Email: [email protected]